Healthpeak price target lowered to $30 from $34 at Stifel

Stifel analyst Stephen Manaker lowered the firm’s price target on Healthpeak to $30 from $34 and keeps a Buy rating on the shares. Stifel believes the stock is undervalued given the stable growth from the company’s existing MOB and Life Science portfolios. While the firm’s current 2023 estimate is at the high end of guidance, Stifel is "comfortable" because it believes the non-same-store portfolio will be stronger than implied at the midpoint.